|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Rocket Pharmaceuticals, Inc.
|
||
Date: January 7, 2021
|
By:
|
/s/ Gaurav Shah, MD
|
Gaurav Shah, MD
|
||
President, Chief Executive Officer and Director
|
Document and Entity Information |
Jan. 04, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 04, 2021 |
Entity Registrant Name | Rocket Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36829 |
Entity Tax Identification Number | 04-3475813 |
Entity Address, Address Line One | 9 Cedarbrook Drive |
Entity Address, City or Town | Cranbury |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08512 |
City Area Code | 646 |
Local Phone Number | 440-9100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001281895 |
Title of 12(b) Security | Common stock, $0.01 par value |
Trading Symbol | RCKT |
Security Exchange Name | NASDAQ |
9T-LO17)VI ME]A>=$%L'4A>XF\CUWAJ\M"6!"SN3WCBO="SWP=]O,_^4%]Q7XP2^/'_4$L# M!!0 ( $ P)U)836XKC+R[,9 CKK1?9!GZ0@B63)!#"VX)D: M*#J%C"!-Y 3T$\E Y83",)AJG0_"4 KZ"CJ?$IF1'A59>!0=Q5$
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
S",810 MZ^N7GW\Z_\7W;V &": P]J8OWM7ES?!AAA(&S;WQPSW["+W/[0[_Y_U.,(@) MBN?0]_E@AGHZXS^F((<>FS3+SS8Y&K06E"[/@F"]7K?7O38F\Z#;Z83!7]]O M'Z,%3(&/LIR"+((MC^'/\N+@+8X +2K>&[Z9DD0FZ 6[N2H1_'^^A/G\D!]V M_5[8WN1Q2Y3(PQ:32/BFA!> =OT(3N #G'G\ M]Q\/H\K1_8 C@@S26S"%"9NR&$Y?EG#0RE&Z3* \MB!P9LZ3$+)+PU>GSU :VGK2KY[S55FISA\AU7> MF^;XHL>0(!Q?9?';%ZY/]5K%/U) WL$JY ?X.8@A M8BJ'??[!YQ_\3BCVNP_LT+\7F-T(#* FQ8)W*E QIX[$)(9DT.KP.SHV< 8)$2=<3=U%T ]<0A1*ZLT)!3.^7@BSKE& M";Q;I5-(C#8IAQ5/[(==-4 E!2NU]T<+:7\]$6DG8#.*&4$T0]OV7(W.#5A% M]$JLJPZP(V=EA\I4PAN?3L0;PSAF='/QBSTQP]#HBQJ ] MG0_ZI^6#"_;QGDSP.JMS01EE\L ^RG$'5!(Z1/_])+)3Y'[;3Z%0/-7 B_C'.*4C^0 ZP?WN(M_+ MA@0"@_ZFD/P#I!)R3^.:TAM454=*'=WO]?$7M)+Q F?F7E]56"Q*.>R>I@T4 M&G0MCY;:NM_L^Y,@2F%V@=-TE8FN5*X)7(L12U2!<4]J&S(->E>DD**[W\5[ MQ F*$$79_#N[M20())KBU0"Q0B: >UHWTF@0VC1>JNQ^CVY,(+ )A+#-FD5]SOYMWA"0'\6P./+^D4)X9WN6H08KF,"/=,T$RD07=C OF^ MSZET[JY22.:,PPW!:[I@/EZ"S-RHJ44JS^P52/ 08 !R8VMT+3(P,C$P,3 T7VQA8BYX;6Q0 M2P$"% ,4 " ! ,"=2/ KJE>\% "E/P %0 @ &U(0 K &UL4$L%!@ $ 0 !@$ -